Reduced-intensity stem cell transplant with JAK inhibitor for myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests giving a JAK inhibitor before and after a reduced-intensity stem cell transplant to treat primary or secondary myelofibrosis. The goal is to improve disease control while using a less harsh transplant approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 to 70, and you have primary myelofibrosis or secondary myelofibrosis
- Your risk level is intermediate-1, intermediate-2, or high (measured by a standard risk score)
- You must be a good candidate for a stem cell transplant based on your overall health and ability to consent
- You must be able to take a JAK inhibitor for at least 8 weeks before transplant and continue for 9–12 months if tolerated
- Your heart, kidneys, liver, and lungs must meet safety thresholds (for example, kidney function needs to be sufficient, and you can’t need oxygen)
- A suitable donor must be available, and you must not have certain infections or prior transplants
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking the drug ruxolitinib before, during, and after a stem cell transplant helps older patients with myelofibrosis or certain related blood disorders. The goal is to see if this approach can improve transplant success and reduce side effects.
This study tests a new drug called LY5830966 for people with myelofibrosis whose disease has not responded to or has returned after treatment with a type I JAK2 inhibitor. The drug aims to help reduce symptoms and improve outcomes.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
This trial tests whether the drug momelotinib, given before and after a stem cell transplant (also called a bone marrow transplant), can help people with myelofibrosis. The hope is that it will make the transplant safer and more effective.
This trial tests a higher dose of ruxolitinib before a stem cell transplant for people with myelofibrosis who have an enlarged spleen. It aims to see if this approach helps the transplant work better.
This trial studies whether an allogeneic (donor) stem cell transplant can help people with higher-risk myelofibrosis (fibrosis in the bone marrow). It looks at outcomes in different donor types as determined by matching rules and patient risk level.
Hear when a new Primary Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.